title: Neonatal community-acquired pneumonia: pathogens and treatment.
abstract: OBJECTIVE
  To analyse the bacterial pathogens and drug sensitivities for neonatal community-acquired pneumonia.
  
  
  METHODS
  Seven hundred sixty sputum samples from newborns with community-acquired pneumonia were cultured to determine microbial organisms present and their drug sensitivities.
  
  
  RESULTS
  Of the 760 specimens, 425 grew pathogens for a 55.9% positive rate. Among the 425 positive cultures, 278 grew gram-negative organisms (65.4%), 142 grew gram-positive organisms (33.3%), while 5 grew fungus (1.3%). The most common gram-negative organisms were Escherichia coli, Klebsiella pneumoniae and Hemophilus influenzae, while the most common gram-positive organisms were Staphylococcus aureus, Staphylococcus epidermidis and Staphylococcus haemolyticus. To the gram-negative organisms, the most sensitive drugs were meropenem, imipenem and amikacin, while to the gram-positive ones were vancomycin, teicoplanin and quinupristin/dalfopristin.
  
  
  CONCLUSIONS
  The most common causative bacteria were gram-negative organisms, which were highly sensitive to Meropenem, Imipenem and Amikacin, yet often treatable with more focused antibiotic coverage, which depended on the bacterium identified.
authors.affiliation: Department of Pediatrics, West China Second University Hospital, Sichuan University, Sichuan, China.
authors.forename: Hua
authors.initials: H
authors.lastname: Wang
authors.forename: Jun
authors.initials: J
authors.lastname: Tang
authors.forename: Ying
authors.initials: Y
authors.lastname: Xiong
authors.forename: Xihong
authors.initials: X
authors.lastname: Li
authors.forename: Fernando
authors.initials: F
authors.lastname: Gonzalez
authors.forename: Dezhi
authors.initials: D
authors.lastname: Mu
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002681:China; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000382:microbiology*; D024881:Drug Resistance, Bacterial; D005260:Female; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D007231:Infant, Newborn; D008297:Male; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology*; D012189:Retrospective Studies; D013183:Sputum / Q000382:microbiology; D013845:Thienamycins / Q000627:therapeutic use; D014640:Vancomycin / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D013845:Thienamycins; D014640:Vancomycin; D015378:Imipenem; D000077731:Meropenem